All News
Dr. Antoni Chan synovialjoints ( View Tweet)
Catherine Sims, MD DrCassySims ( View Tweet)
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Antoni Chan synovialjoints ( View Tweet)
Practical use of JAK inhibitors in select groups in Axial SpA
A new treatment for AxSpA that has come on the scene are JAK inhibitors. In clinic, considerations for JAKi use are body mass index, smoking status, prior use of biologics and patients with high inflammatory states such as high CRP and inflammatory change on MRI scan of the spine and sacroiliac joints. There are further studies at #ACR22 which help answer these questions.
Read ArticleCatherine Sims, MD DrCassySims ( View Tweet)
Industry Abstract Previews of ACR 2022
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list.
Read ArticleUpdate: axSpA Recommendations
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.
Read Article2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
Read ArticleWomen with Rheumatic Disease (11.4.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Read ArticleCan You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?
Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA).
Read Article